Half-life is the time required for the plasma concentration of a substance to decrease by 50 percent following administration in a controlled preclinical study. The parameter has been studied extensively in published pharmacokinetic literature, almost entirely in animal models and in vitro preparations, and is a foundational concept for understanding how a research peptide behaves over time in those experimental systems. For research laboratories sourcing material from originlabsresearch.com, half-life is one of several parameters that have been characterised in published preclinical studies and that inform the design of in vitro and animal-model research protocols, the timing of sample collection, and the interpretation of observed effects under those specific experimental conditions. This guide summarises published preclinical half-life values for representative peptides in the catalog as research reference data and explains the underlying pharmacokinetic concepts. It must be emphasised at the outset that this guide does not provide human dosing recommendations, does not describe human protocols, and does not constitute medical, clinical, or veterinary advice. The peptides discussed here are supplied for research purposes only and are not for human use. Investigators typically design dosing arms in animal-model studies based on published preclinical references and species-specific allometric considerations, and all in vivo work is the responsibility of the principal investigator working under appropriate institutional oversight and regulatory approval. The half-life values cited are drawn from published preclinical pharmacokinetic literature and represent values observed under the specific experimental conditions of those studies. Variability across species, formulations, routes of administration, and individual subjects has been documented in the literature and should be taken into account in any research planning that uses these values as reference points.
What half-life means in pharmacokinetics
Half-life in pharmacokinetics is a derived parameter that summarises how quickly a substance is cleared from circulation following administration in a controlled preclinical study. After a peptide enters the bloodstream of an experimental subject, its concentration declines over time due to a combination of distribution into tissues, metabolic transformation, and excretion. The elimination phase of this concentration-time curve is commonly modelled as first-order kinetics, where the rate of decline is proportional to the concentration present. Under first-order kinetics, the half-life is constant regardless of the starting concentration, and is calculated from the elimination rate constant. Investigators measure half-life by collecting serial plasma samples in animal-model preparations and fitting a curve to the resulting concentration-time data. Half-life is reported in units of time, most commonly minutes or hours for peptides, and provides a quick indication of the temporal scale on which the substance is active in the experimental system. Peptides with very short half-lives in published animal-model studies, on the order of minutes, are typically degraded rapidly by circulating peptidases or removed by the kidneys in the experimental preparations studied. Peptides with longer half-lives, on the order of hours or days in published preclinical reports, have typically been engineered to resist enzymatic degradation, often by incorporating non-natural amino acids, fatty acid acylation for albumin binding, or sequence modifications at known protease cleavage sites. The half-life of a research peptide as reported in the preclinical literature is a defining feature of its pharmacokinetic profile and is referenced in in vitro and animal-model study design for sample collection timing and modelling of exposure behaviour.
Published half-life data for BPC-157 and TB-500 in preclinical studies
BPC-157 is a 15-amino acid synthetic peptide derived from a sequence in human gastric juice protein. It has been investigated in preclinical studies as a research compound with reported activity in animal models of soft tissue repair and gastrointestinal mucosal integrity. The plasma half-life of BPC-157 in rodent pharmacokinetic studies has been referenced in published animal-model research as relatively short, typically in the range of less than 30 minutes following intraperitoneal administration in rat preparations. Despite the short plasma half-life observed in those animal studies, the duration of measured biological effect in the same research models has been described in the literature as longer than the plasma half-life alone would suggest, and several mechanisms have been proposed in the preclinical literature including local tissue retention and downstream signalling cascades that persist after the parent peptide is cleared from rodent plasma. TB-500 refers to the synthetic truncated active fragment of thymosin beta-4, a 43-amino acid peptide that has been investigated in research models of wound healing and angiogenesis. The plasma half-life of thymosin beta-4 in rodent studies has been referenced in the range of one to two hours following parenteral administration in those preparations, with the truncated fragment showing similar pharmacokinetic behaviour in published preclinical reports. The peptide is rapidly distributed into tissues in the animal models studied, where it has been described as accumulating in injured or remodelling regions. As with BPC-157, the duration of observable research effect in the animal-model literature exceeds the plasma half-life, indicating that simple plasma half-life is not the only relevant temporal parameter for these peptides in preclinical study design.
GHRH analogs and growth hormone secretagogues in preclinical literature
GHRH analogs and growth hormone secretagogues are a family of research peptides that have been investigated in animal-model studies for their interaction with hypothalamic and pituitary signalling pathways relevant to growth hormone release. CJC-1295 without DAC is a synthetic analog of growth hormone releasing hormone with sequence modifications that resist enzymatic degradation. Its plasma half-life in published preclinical pharmacokinetic studies has been referenced as approximately 30 minutes following parenteral administration in the animal models studied. The DAC-modified version of CJC-1295 incorporates a drug affinity complex that promotes binding to circulating albumin, dramatically extending the plasma half-life into the range of multiple days in published preclinical reports. Sermorelin is a shorter GHRH analog that has been investigated with a plasma half-life referenced in published animal-model literature in the range of 10 to 20 minutes. Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that has been studied in preclinical pharmacokinetic models with a plasma half-life referenced as approximately two hours following parenteral administration in those experimental systems. Hexarelin is a hexapeptide growth hormone secretagogue with a plasma half-life referenced in similar preclinical literature as approximately one hour. These published preclinical half-life values reflect the variability across the secretagogue family observed in animal-model studies and inform the design of in vitro and animal-model research protocols where the temporal pattern of peptide exposure is a relevant variable in the experimental design. None of these values constitute guidance for human use.
Incretin pathway peptides in published preclinical and trial data
Incretin pathway peptides are a class of research compounds that interact with receptors involved in glucose homeostasis and energy balance signalling, including GLP-1 receptors, GIP receptors, and glucagon receptors. The pharmacokinetic profiles of peptides in this class have been engineered for extended duration of action through modifications such as fatty acid acylation, which promotes binding to circulating albumin and resistance to dipeptidyl peptidase-4 mediated cleavage. Semaglutide is a long-acting GLP-1 receptor agonist with a plasma half-life that has been reported in published preclinical and clinical pharmacokinetic literature as approximately seven days under the controlled conditions of those studies. Tirzepatide is a dual GIP and GLP-1 receptor agonist with a plasma half-life reported in published literature as approximately five days. Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors that has been characterised in published phase clinical research with a reported plasma half-life of approximately six days in the studies referenced. The extended half-lives reported for these compounds in published literature reflect the deliberate engineering of the molecules for sustained exposure profiles. These half-life values are presented here strictly as published research reference data. They are not dosing guidance, are not a recommendation for human use, and are not a description of any human protocol. Any application of any compound in human subjects is determined by regulatory authorities based on the totality of pharmacological, safety, and tolerability data from controlled trials, and requires appropriate regulatory authorisation.
MOTS-c, melanotan, and shorter peptides in preclinical reports
Several additional peptides in the originlabsresearch.com catalog have been characterised in published pharmacokinetic literature, almost entirely in animal-model preparations. MOTS-c is a 16-amino acid mitochondrial-derived peptide that has been investigated in research models of metabolic signalling. Its plasma half-life following parenteral administration in published preclinical animal studies has been referenced in the range of one to two hours. Melanotan II is a cyclic heptapeptide analog of alpha-melanocyte stimulating hormone that has been investigated in research models of melanocortin receptor signalling. Its plasma half-life in published animal-model studies has been referenced as approximately 30 minutes to one hour. PT-141, also known as bremelanotide, is a related melanocortin receptor agonist with a reported plasma half-life of approximately two hours in published pharmacokinetic data. Selank and Semax are short neuropeptide research compounds with plasma half-lives referenced in the range of minutes to tens of minutes following parenteral administration in the preclinical preparations studied, with the intranasal route producing different pharmacokinetic profiles than parenteral routes in those animal models. GHK-Cu is a copper-binding tripeptide with a relatively short plasma half-life on the order of minutes in published animal-model studies, with local tissue retention referenced as exceeding the plasma half-life. The variability across these compounds in published preclinical literature illustrates that half-life is sequence-dependent and route-dependent, and any in vitro or animal-model research protocol design should reference the specific pharmacokinetic data published for the peptide and route in question. None of the values cited in this guide constitute dosing advice for humans.
References
- [1] Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, et al (2010). Stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. PMID 20388123
- [2] Goldstein AL, Hannappel E, Sosne G, Kleinman HK (2012). Thymosin beta4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. PMID 22506662
- [3] Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, et al (2015). Discovery of the once-weekly glucagon-like peptide-1 analogue semaglutide. Journal of Medicinal Chemistry. PMID 26308095
- [4] Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. Molecular Metabolism. PMID 30473097
- [5] Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al (2023). Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. New England Journal of Medicine. PMID 37366315
Frequently asked questions
What is plasma half-life in preclinical pharmacokinetics?
Plasma half-life is the time required for the concentration of a substance in plasma to decrease by 50 percent following administration in a preclinical experimental system. It is a derived pharmacokinetic parameter that summarises how quickly the substance is cleared from circulation under the controlled conditions of the study.
Does a short half-life in animal models mean the effect is brief?
Not necessarily. Several research peptides have been described in the preclinical literature as producing measurable biological effects in animal models that persist beyond their plasma half-life, due to local tissue retention or downstream signalling cascades.
Why do some peptides have published half-lives of days while others are minutes?
Engineered peptides such as semaglutide and tirzepatide incorporate fatty acid acylation and sequence modifications that resist enzymatic degradation and promote albumin binding, extending the half-life substantially compared to native sequences in the studies reported.
Does this guide provide dosing recommendations?
No. This guide summarises published preclinical pharmacokinetic data as research reference material only. It does not provide human dosing recommendations, does not describe human protocols, and does not constitute medical, clinical, or veterinary advice.
How variable are published half-life values across studies?
Published half-life values vary across species, formulations, routes of administration, and individual subjects in animal-model studies. They represent observations under specific experimental conditions and should be interpreted as research reference points rather than absolute constants.
What is the reported half-life of Retatrutide in published literature?
Retatrutide has been characterised in published clinical research with a plasma half-life of approximately six days, consistent with its engineering as a long-acting triple agonist. This value is published research reference data, not dosing guidance.
Why is published half-life data relevant to in vitro and animal-model protocol design?
Published half-life informs investigators designing animal-model studies in timing of sample collection, design of repeated-administration schedules in preclinical preparations, and modelling of exposure behaviour, all of which are relevant variables in preclinical pharmacokinetic and pharmacodynamic research.
